CGT1145 / Cogent Biosci - LARVOL DELTA

Anticipated Upcoming Milestones (Cogent Biosciences Press Release) - "(i) Submit Investigational New Drug (IND) applications for CGT1815, Cogent’s novel, selective pan-KRAS(ON) inhibitor, and CGT1145, Cogent’s novel, selective JAK2 V617F inhibitor; (ii) Complete dose escalation for CGT4255, Cogent’s CNS-penetrant, selective mutant ErbB2 inhibitor."

IND • JAK2V617F • Trial status • Oncology • Solid Tumor

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress (Cogent Biosciences Press Release) - "Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings; Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation."

JAK2V617F • P2 data • Preclinical • Aggressive Systemic Mastocytosis • Mast Cell Leukemia • Myeloproliferative Neoplasm

PRECLINICAL CHARACTERIZATION OF CGT1145, A NOVEL, WILD-TYPE-SPARING, JAK2 V617F MUTANT-SELECTIVE INHIBITOR (EHA 2026) - "Approved JAK2 inhibitors, such as ruxolitinib, are kinase domain binders that can alleviate symptoms and improve outcomes in patients with MPNs. Summary/Conclusion CGT1145 is a potential best-in-class, JAK2 WT sparing, JAK2 V617F JH2 mutant-selective inhibitor that has the potential to provide significantly higher target engagement compared to approved JAK inhibitors. By selectively inhibiting JAK2 V617F signaling while preserving JAK2 WT signaling, CGT1145 has the potential to more effectively eradicate JAK2 V617F MPN-propagating cells, induce molecular remission, and minimize toxicities associated with non-selective JAK inhibition."

Preclinical • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • ABL1 • BCR • JAK2 • STAT5

Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor (ASH 2025) - "Clinically approved JAK2 inhibitors, suchas ruxolitinib, are kinase domain (JH1) binders that effectively alleviate symptoms and improve outcomesin patients with myeloproliferative neoplasms. CGT1145 is a potential best-in-class JAK2 WT sparing, JAK2 V617F JH2 mutant selectiveinhibitor that has the potential to provide significantly higher target engagement which may lead toimprovements in the ability to eradicate JAK2 V617F MPN-propagating cells and induce molecularremission while avoiding hematological tolerability issues. Further studies are ongoing to assessCGT1145, as well as other advanced close in analogs in our lead series."

Preclinical • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • ABL1 • BCR • JAK2 • STAT5

Multiple bezuclastinib abstracts selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH); SUMMIT data in NonAdvSM selected for two oral presentations (Cogent Biosciences Press Release) - "'On top of this progress, we recently presented updated preclinical data from our research pipeline that demonstrated potential best-in-class attributes of our pan-KRAS inhibitor and plan to describe for the first time at ASH 2025 our highly potent, highly selective JAK2 V617F mutant-selective inhibitor. Both of these programs are on track for IND in 2026.'"

Clinical data • IND • JAK2V617F • Preclinical • Hematological Malignancies